JAM
NBIX icon

Jupiter Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Jupiter Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-582,789
Closed -$67.1M – 444
2024
Q3 		$67.1M Buy
582,789
+275,689
+90% +$37.8M 0.59% 46
2024
Q2 		$42.3M Buy
307,100
+88,634
+41% +$12.2M 0.4% 83
2024
Q1 		$30.1M Buy
218,466
+8,375
+4% +$1.14M 0.29% 115
2023
Q4 		$27.7M Buy
210,091
+119,181
+131% +$13.7M 0.27% 107
2023
Q3 		$10.2M Sell
90,910
-236,882
-72% -$24.9M 0.11% 199
2023
Q2 		$30.9M Buy
327,792
+17,893
+6% +$1.75M 0.34% 78
2023
Q1 		$31.4M Buy
309,899
+247,248
+395% +$25.7M 0.43% 69
2022
Q4 		$7.47M Buy
62,651
+50,498
+416% +$5.91M 0.11% 194
2022
Q3 		$1.29M Buy
12,153
+7,094
+140% +$720K 0.02% 379
2022
Q2 		$493K Buy
+5,059
New +$467K 0.01% 489
2021
Q3 		– Sell
-37,000
Closed -$3.6M – 616
2021
Q2 		$3.6M Hold
37,000
– – 0.04% 344
2021
Q1 		$3.6M Hold
37,000
– – 0.04% 360
2020
Q4 		$3.54M Hold
37,000
– – 0.04% 363
2020
Q3 		$3.56M Buy
+37,000
New +$4.28M 0.04% 351

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jupiter Asset Management's NBIX Position: Q4 2024 in Review

Jupiter Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 582,789 shares — an estimated $67.1M sold.

Jupiter Asset Management first reported a position in NBIX in Q3 2020 and held it in 14 quarters. The position peaked at $67.1M in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Jupiter Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Jupiter Asset Management sold 582,789 Neurocrine Biosciences shares in Q4 2024, an estimated $67.1M.
  • Jupiter Asset Management first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 14 quarters.
  • Jupiter Asset Management's Neurocrine Biosciences position peaked at $67.1M in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Jupiter Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.